Aurore Garde

Aurore Garde

Auto-generated profile, based on publicly available information

Aurore Garde

Université Bourgogne Europe, CHU Dijon Bourgogne, Inserm, CTM UMR1231, équipe GAD, FHU TRANSLAD, Centre de génétique, Centre de référence Anomalies du Développement et Syndromes Malformatifs, Centre de référence Déficiences Intellectuelles de Causes Rares, et Centre de référence GénoPsy, Dijon, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2022 in Genetics in Medicine
Verified
Journal Article
Open access
SKSayaka Kayumi
Sayaka Kayumi
LPLuis A. Pérez-Jurado
Luis A. Pérez-Jurado
MPMaría Palomares
María Palomares
SRSneha Rangu
Sneha Rangu
SSSarah E. Sheppard
Sarah E. Sheppard
MCMark Corbett
Mark Corbett
Germline loss-of-function variants in CTNNB1 cause neurodevelopmental disorder with spastic diplegia and visual defects (NEDSDV; OMIM 615075) and are the most frequent, recurrent monogenic cause of cerebral palsy (CP). We investigated the range of clinical phenotypes owing to disruptions of CTNNB1 to determine the association between NEDSDV and CP. Genetic information from 404 individuals with collectively 392 pathogenic CTNNB1 variants were ascertained for the study. From these, detailed phenotypes for 52 previously unpublished individuals were collected and combined with 68 previously published individuals with comparable clinical information. The functional effects of selected CTNNB1 missense variants were assessed using TOPFlash assay. The phenotypes associated with pathogenic CTNNB1 variants were similar. A diagnosis of CP was not significantly associated with any set of traits that defined a specific phenotypic subgroup, indicating that CP is not additional to NEDSDV. Two CTNNB1 missense variants were dominant negative regulators of WNT signaling, highlighting the utility of the TOPFlash assay to functionally assess variants. NEDSDV is a clinically homogeneous disorder irrespective of initial clinical diagnoses, including CP, or entry points for genetic testing.

15 May 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CGCharlotte Gehin
Charlotte Gehin
MLMuseer Lone
Museer Lone
WLWinston Lee
Winston Lee
LCLaura Capolupo
Laura Capolupo
SHSylvia Ho
Sylvia Ho
VGVincenzo A. Gennarino
Vincenzo A. Gennarino
Neural differentiation, synaptic transmission, and action potential propagation depend on membrane sphingolipids, whose metabolism is tightly regulated. Mutations in the ceramide transporter CERT (CERT1), which is involved in sphingolipid biosynthesis, are associated with intellectual disability, but the pathogenic mechanism remains obscure. Here, we characterize 31 individuals with de novo missense variants in CERT1. Several variants fall into a previously uncharacterized dimeric helical domain that enables CERT homeostatic inactivation, without which sphingolipid production goes unchecked. The clinical severity reflects the degree to which CERT autoregulation is disrupted, and inhibiting CERT pharmacologically corrects morphological and motor abnormalities in a Drosophila model of the disease, which we call ceramide transporter (CerTra) syndrome. These findings uncover a central role for CERT autoregulation in the control of sphingolipid biosynthetic flux, provide unexpected insight into the structural organization of CERT, and suggest a possible therapeutic approach for patients with CerTra syndrome.

7 January 2021 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
AGAurore Garde
Aurore Garde
LGLaurent Guibaud
Laurent Guibaud
AGAlice Goldenberg
Alice Goldenberg
FPFlorence Petit
Florence Petit
RDRodolphe Dard
Rodolphe Dard
LFLaurence Faivre
Laurence Faivre

5 December 2020 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
AGAurore Garde
Aurore Garde
JCJenny Cornaton
Jenny Cornaton
ASArthur Sorlin
Arthur Sorlin
SMSébastien Moutton
Sébastien Moutton
CNClaire Nicolas
Claire Nicolas
LFLaurence Faivre
Laurence Faivre

30 March 2026 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ELElsa Leitão
Elsa Leitão
ASAmandine Santini
Amandine Santini
BCBenjamin Cogne
Benjamin Cogne
MEMiriam Essid
Miriam Essid
MAMaria Athanasiadou
Maria Athanasiadou
CNCaroline Nava
Caroline Nava
Small nuclear RNAs (snRNAs) are essential components of the spliceosome. De novo variants in snRNA genes RNU4-2 (ReNU syndrome), RNU5B-1 and RNU2-2 have been linked to dominant neurodevelopmental disorders (NDDs), revealing a large unexpected contribution of noncoding RNA genes to genetic diseases. Here, through international collaborations, we analyze systematically 200 potentially functional snRNA genes in a French cohort of 34,329 people with rare disorders. We report RNU2-2 variants in 141 individuals, including 35 with recurrent dominant pathogenic variants and 91 affected members from 73 families with biallelic variants. Recessive RNU2-2 NDD is at least twice as frequent as the dominant form and often involves a de novo variant in trans with an inherited allele, consistent with the high mutability of snRNA genes. Dominant and recessive RNU2-2 NDDs share overlapping clinical features, with frequent epilepsy. Blood transcriptomics and DNA methylation analyses revealed subtle, variant-specific effects on splicing and episignatures. Our results support a gradient-of-impact model bridging dominant and recessive inheritance, and establish RNU2-2 variants as a principal contributor to NDDs, nearly as prevalent as ReNU syndrome.

9 February 2022 in Annals of Human Genetics
Verified
Journal Article
Closed access
PDF file
ETEmilie Tisserant
Emilie Tisserant
AVAntonio Vitobello
Antonio Vitobello
DCDavide Callegarin
Davide Callegarin
SVSimon Verdez
Simon Verdez
ABAnge‐Line Bruel
Ange‐Line Bruel
PCPatrick Callier
Patrick Callier